VistaGen Therapeutics Inc
NASDAQ: VTGN · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
VistaGen Therapeutics Inc (VTGN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $95.00 | $23060.00 | $1376.00 | $2200.00 | $341600.00 | $881500.00 | $263700.00 | $269700.00 | $989800.00 | $3.71M | $11.28M | $14.01M | $5.77M | $108.28M | $74.64M | $21.09M | $123.65M | $84.34M |
| Cash & equivalents | $95.00 | $21812.00 | $556.00 | $1808.00 | $81000.00 | $638100.00 | $-6000.00 | $70000.00 | $428500.00 | $2.92M | $10.38M | $13.10M | $1.36M | $103.11M | $68.14M | $16.64M | $119.17M | $67.13M |
| Current assets | $95.00 | $21812.00 | $556.00 | $1808.00 | $238100.00 | $671800.00 | $40500.00 | $105700.00 | $855300.00 | $3.38M | $11.02M | $13.65M | $1.58M | $104.12M | $71.00M | $17.51M | $120.67M | $82.08M |
| Total liabilities | $240.00 | $2686.00 | $1500.00 | $3200.00 | $6.05M | $13.44M | $13.06M | $20.81M | $3.97M | $3.10M | $4.36M | $6.94M | $11.50M | $16.30M | $9.93M | $9.01M | $9.37M | $13.95M |
| Current liabilities | $240.00 | $2686.00 | $1500.00 | $3200.00 | $3.18M | $2.41M | $5.21M | $17.39M | $1.79M | $1.37M | $1.46M | $2.80M | $2.77M | $4.19M | $5.77M | $4.57M | $5.12M | $12.61M |
| Long-term debt | — | — | — | — | $2.76M | $4.40M | $3.92M | $331800.00 | $27200.00 | $12000.00 | $9000.00 | — | — | — | — | — | — | — |
| Shareholder equity | $-145.00 | $20374.00 | $-124.00 | $-1000.00 | $-5.71M | $-12.56M | $-12.80M | $-20.54M | $-2.98M | $615800.00 | $6.92M | $7.08M | $-5.73M | $91.98M | $64.72M | $12.08M | $114.29M | $70.39M |
| Retained earnings | $-10245.00 | $-26661.00 | $-48659.00 | $-57635.00 | $-54.78M | $-67.67T | $-70.64B | $-84.52M | $-131.74M | $-142.00M | $-156.54M | $-181.13M | $-201.91M | $-219.84M | $-267.60M | $-326.85M | $-356.21M | $-407.63M |
| Accounts receivable | — | — | — | — | $106200.00 | — | $2800.00 | — | — | — | — | $300000.00 | — | $40600.00 | $2.75M | $802700.00 | — | — |
| Inventory | — | — | — | — | $0.00 | $0.00 | $31200.00 | $0.00 | $0.00 | $0.00 | $0.00 | $230400.00 | — | $942200.00 | $2.45M | $-735600.00 | — | — |
| Goodwill | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
Frequently asked questions
What is VistaGen Therapeutics Inc's revenue?
VistaGen Therapeutics Inc's trailing twelve-month revenue is $789000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is VTGN?
In its most recent fiscal year, VTGN ran a gross margin of 100.00%, an operating margin of -11,517.08%, and a net margin of -10,579.84%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does VTGN generate?
VTGN produced $-42.29M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is VTGN's balance sheet healthy?
VTGN holds $67.13M in cash and equivalents against — in long-term debt, on $70.39M of shareholder equity. That debt is best read against the cash flow the business throws off each year.